Sign Out
Pregnancy: Pregnancy Category B. There are no adequate or well-controlled studies in pregnant women. The safe use in pregnancy has not been established. However, oral Co-amoxiclav has been administered to pregnant women, particularly in the treatment of urinary tract infections, without evidence of adverse effects to the fetus.
In a single study in women with preterm, premature rupture of the fetal membrane (pPROM), it was reported that prophylactic treatment with Co-amoxiclav may be associated with an increased risk of necrotizing enterocolitis in neonates. Co-amoxiclav use should be avoided in pregnancy unless considered essential by the physician.
Lactation: Co-amoxiclav is distributed in human milk and may cause diarrhea, fungal infection of the mucous membrane and sensitization in the breastfed infant. Caution should be exercised if Co-amoxiclav is to be administered to a nursing mother.
Continue with Google